15  US 6,503,413 B2  16  wherein  R  $^{1 }$is derived from oleic acid, and the compound is  available from Witco Company.  An example of Compound (11) is l-ethyl-1-(2- hydroxyethyl)-2-isoheptadecylimidazolinium ethylsulfate  wherein  R 1  is a C$_{17 }$ hydrocarbon group,  R 2  is an ethylene  group,  R $^{5 }$is an ethyl group, and  A- is an ethylsulfate anion.  In the cationic nitrogenous salts herein, the anion  A-,  which is any compatible anion, provides electrical neutrality.  Most often, the anion used to provide electrical neutrality in  these salts is from a strong acid, especially a halide, such as  chloride, bromide, or iodide. However, other anions can be  used, such as methylsulfate, ethylsulfate, acetate, formate,  sulfate, carbonate, and the like. Chloride and methylsulfate  are preferred herein as anion A-. The anion can also, but less  preferably, carry a double charge in which case  A- repre› sents half a group.  2. Biguanide Compounds  Other useful cationic surfactants herein include biguanide  compounds.  As  with the quaternary compounds described  hereinbefore, many biguanide compounds exhibit antimi› crobial effectiveness, depending on the level of the bigu› anide compound in the compositions. Especially useful  biguanide compounds include 1,1’-hexamethylene bis(S-(p› chlorophenyl)biguanide ), commonly known as  chlorhexidine, and its salts, e.g., with hydrochloric, acetic  and gluconic acids. The digluconate salt is highly water› soluble, about 70% in water, and the diacetate salt has a  solubility of about 1.8% in water. When chlorhexidine is  used as a cationic surfactant in dilute versions of the present  invention, it is typically present at a level from about  0.0001 % to about 10%, preferably from about 0.001 % to  about 7%, and more preferably from about 0.01 % to about  5%, by weight of the composition. When used in concentrate  versions of the present invention, it is typically present at a  level from about 0.001 % to about 70%, preferably from  about 0.01 % to about 60%, and more preferably from about  0.1 % to about 50%, by weight of the composition. In some  cases, a level from about 0.001 % to about 10% in the dilute  compositions and a level from about 0.01 % to about 70% in  the concentrate compositions may be needed for antimicro› bial and/or virucidal activity.  Other useful biguanide compounds include Cosmocifi  CQfi, Vantocilfi IB, including poly (hexamethylene  biguanide) hydrochloride. Other useful cationic surfactants  include the bis-biguanide alkanes. Usable water soluble salts  of the above are chlorides, bromides, sulfates, alkyl sul› fonates such as methyl sulfonate and ethyl sulfonate, phe› nylsulfonates such as p-methylphenyl sulfonates, nitrates,  acetates, gluconates, and the like.  Examples of suitable bis biguanide compounds are chlo› r hexidine; 1, 6-bis-(2-e thy lhexy lbiguanidohexane)  dihydrochloride; 1,6-di-(N$_{1}$,N$_{1}$’-phenyldiguanido-N 5 ,N 5 ’)› hexane tetrahydrochloride; 1,6-di-(N $_{1}$,N $_{1}$’-phenyl-N $_{1}$,N i’› methyldiguanido-N5,N5’)-hexane dihydrochloride; 1,6-di  (N  $_{1}$,N  $_{1 }$’-o-chlorophenyidiguanido-N  5 ,N  5  ’)hexane  dihydrochloride;  1,6-di(N  1 ,N $_{1 }$’-2,6- dichlorophenyidiguanido-N  5  ,N  5  ’)hexane dihydrochloride;  1,6-di[N$_{1}$,N/-.beta.-(p-methoxyphenyl) diguanido-N 5 ,N 5 ’]› hexane dihydrochloride; 1,6-di(N $_{1}$,N $_{1}$’-.alpha.-methyl-.  beta.-phenyldiguanido-N 5 ,N 5 ’)-hexane dihydrochloride;  1,6-di(N $_{1}$,N $_{1 }$’-p-nitropheny  ldiguanido-N  5 ,N  5  ’)hexane  dihydrochloride; .omega.: .omega. ’-di-(N  $_{1 }$,N 1  ’› p hen yldigu anido -N  5 ,  N  5  ’)-di-n-p rop yle the r  dihydrochloride;. omega: omega’ -di(N  $_{1 }$,N $_{1 }$’-p› chlorophenyidiguanido-N,N’)-di-n-propylether tetrahydro› chloride; 1,6-di(N $_{1}$,N $_{1 }$’-2,4-dichlorophenyldiguanido-N  5 ,  N 5 ’)hexane tetrahydrochloride; 1,6-di(N$_{1}$ ,N/-p› methylphenyldiguanido-N  5 ,N  5  ’)hexane dihydrochloride;  1,6-di(N $_{1}$,N $_{1 }$’-2,4,5-trichlorophenyldiguanido-N  5 ,N  5  ’)  hexane tetrahydrochloride; 1,6-di[N$_{1}$ ,N$_{1}$ -.alpha.-(p› chlorophenyl) ethyldiguanido-N 5 ,Ns’] hexane  dihydrochloride; .omega.: .omega.’di(N  1 ,N i’-p› chlorophenyldiguanido-N  5 ,N  5 ’)m-xylene dihydrochloride;  1,12-di(N$_{1}$,N/-p-chlorophenyldiguanido-N 5 ,N 5 ’) dodecane  dihydrochloride; 1,10-di(N $_{1}$,N i’-phenyldiguanido-N  5 ,N  5 ’)› d e cane tetrahydrochloride; 1,12-di(N$_{1}$ ,Ni’- $^{phenyldiguanido-N}$5,N 5 ’) dodecane tetrahydrochloride; 1,6- di(N $_{1}$,N $_{1 }$’-o-chlorophenyldiguanido-N  5 ,N  5 ’) hexane  dihydrochloride; 1,6-di(N $_{1}$,N $_{1 }$’-p-chlorophenyldiguanido› N  5,N 5’)-hexane tetrahydrochloride; ethylene bis (1-tolyl  biguanide ); ethylene bis(p-tolyl biguanide ); ethylene bis(3,  5-dimethylphenyl biguanide ); ethylene bis(p-tert› amylphenyl biguanide); ethylene bis(nonylphenyl  biguanide); ethylene bis(phenyl biguanide); ethylene bis(N› butylphenyl biguanide ); ethylene bis(2,5-diethoxyphenyl  biguanide ); ethylene bis(2,4-dimethylphenyl biguanide );  ethylene bis( o-diphenylbiguanide ); ethylene bis(mixed amyl  naphthyl biguanide); N-butyl ethylene bis  (phenylbiguanide ); trimethylene bis( o-tolyl biguanide );  N-butyl trimethylene bis(phenyl biguanide); and the corre› sponding pharmaceutically acceptable salts of all of the  above such as the acetates; gluconates; hydrochlorides;  hydrobromides; citrates; bisulfites; fluorides; polymaleates;  N-coconutalkylsarcosinates; phosphites; hypophosphites;  perfluorooctanoates; silicates; sorbates; salicylates; male› ates; tartrates; fumarates; ethylenediaminetetraacetates; imi- nodiacetates; cinnamates; thiocyanates; arginates; pyromel› litates; tetracarboxybutyrates; benzoates; glutarates;  monofluorophosphates; and perfluoropropionates, and mix› tures thereof. Preferred cationic surfactants from this group  are 1,6-di-(N$_{1}$,N$_{1}$’-phenyidiguanido-N 5 ,N 5 ’)-hexane tetrahy- drochloride; 1,6-di(N  $_{1}$,N $_{1 }$’-o-chlorophenyldiguanido-N  5 ,  N 5 ’)-hexane dihydrochloride; 1,6-di(N$_{1}$ ,N/-2,6- dichlorophenyidiguanido- N $_{5}$,N  5  ’)hexane dihydrochloride;  1,6-di(N $_{1}$,N $_{1 }$’-2,4-dichlorophenyidiguanido-N  5 ,N  5 ’)hexane  tetrahydrochloride; 1,6-di[N $_{1}$,N $_{1}$’-.alpha.-(p-chlorophenyl)  et h y id i g u an id o - N  5 ,  N  5 ’]  hexane  dihydrochloride; .omega.: .omega.’ di(N  $_{1 }$,N 1 ’  -p› chlorophenyidiguanido-N  5 ,N  5 ’)m-xylene dihydrochloride;  1,12-di(N$_{1}$,N/-p-chlorophenyldiguanido-N 5 ,N 5 ’) dodecane  dihydrochloride; 1,6-di(N $_{1}$,N $_{1 }$’-o-chlorophenyidiguanido- $^{N}$5,Ns’) hexane dihydrochloride; 1,6-di(N$_{1}$ ,N/-p› chloropheny ldiguanido- N $_{5}$,N  5  ’)-hexane tetrahydrochloride;  and mixtures thereof; more preferably, 1,6-di(N $_{1}$,N i’-o› chlorophenyidiguanido-N  5 ,N  5 ’)-hexane dihydrochloride;  1,6-di(N $_{1}$,N $_{1 }$’-2,6-dichlorophenyidiguanido-N  5 ,N  5 ’)hexane  d i h y d ro c h 1 o r i de ;  1 , 6 - d i (  N $_{1 }$ ,  N $_{1 }$ ’ - 2 , 4 - dichlorophenyidiguanido-N  5 ,N  5  ’)hexane tetrahydrochlo› r id e;  1,6-di[N$_{1}$ ,N$_{1}$ ’-.alpha.-(p-chlorophenyl)  ethyidiguanido-N 5 ,N 5 ’]  hexane  dihydrochloride; .omega.: .omega.’ di(N  $_{1 }$,N 1 ’  -p- chlorophenyidiguanido-N  5 ,N  5 ’)m-xylene dihydrochloride;  1,12-di(N $_{1}$,N i’-p-chlorophenyidiguanido-N  5 ,N  5 ’) dodecane  dihydrochloride; 1,6-di(N $_{1}$,N $_{1 }$’-o-chlorophenyidiguanido- Anion  A-